Pfizer Drops Twice-Daily Version of Obesity Pill Over Side Effects Pfizer Drops Twice-Daily Version of Obesity Pill Over Side Effects
Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of its midstage trial with high rates of side effects such as nausea and vomiting.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Diabetes | Eating Disorders & Weight Management | Endocrinology | Health | Obesity | Pfizer | Study | Weight Loss